Stella Mental Health Expands Services Through Bespoke Treatment Acquisition

Stella Mental Health Expands Its Reach with Bespoke Treatment Acquisition

As the United States prepares to observe Suicide Prevention Week from September 7 to 13, Stella Mental Health, renowned for its leadership in interventional psychiatry, has taken significant strides by acquiring Bespoke Treatment. This facility, which is accredited by the Joint Commission and based in Los Angeles, offers a holistic approach to mental health, combining traditional psychiatric services with advanced therapeutic options. Founded by the neuroscientist Ben Spielberg in 2019, Bespoke Treatment has established a solid reputation for its commitment to personalized mental health care.

This acquisition is not just a business transaction; it represents a concerted effort to reshape and enhance the delivery of mental health services, particularly in a rapidly changing health landscape. With a focus on both traditional psychiatry and cutting-edge treatments, Bespoke Treatment provides a comprehensive array of services including psychotherapy, general psychiatry, and innovative interventions such as Transcranial Magnetic Stimulation (TMS) and IV Ketamine therapy. More importantly, patients will now have access to Dual Sympathetic Reset Stellate Ganglion Block (DSR-SGB), a revolutionary treatment that targets trauma-related symptoms.

Michael Gershenzon, the CEO of Stella Mental Health, expressed enthusiasm regarding the acquisition, stating, "At Stella, we're committed to pushing the frontiers of mental health care through innovation and scientifically backed strategies. Bespoke Treatment stands out for its individualized approach to patient care, and we're thrilled to infuse our expertise into this dynamic model. Our collaboration aims to broaden the access to transformative mental health treatments in California and beyond."

In turn, Ben Spielberg emphasized Bespoke Treatment's mission to create a seamless mental health experience. "We originated in response to a disjointed mental health system that inadequately served patients," he remarked. Patients often struggled with long delays and inconsistent care pathways. The merger with Stella Mental Health solidifies their mission, allowing for even more tailored treatment plans through a dedicated interdisciplinary team and the addition of therapies like DSR-SGB.

Crucial to this evolution is Dr. Nima Fahimian, the Chief Medical Officer at Bespoke Treatment. His extensive experience as a triple board-certified professional in Psychiatry, Addiction Medicine, and Integrative and Holistic Medicine, as well as his tenure at prestigious institutions such as Cedars-Sinai, positions him to spearhead clinical care and innovation post-acquisition. His work within the Veterans Affairs system, where he advocates for the use of the stellate ganglion block in treating PTSD, aligns perfectly with the new mission of Stella Mental Health to integrate advanced therapies into their operations.

Currently, Stella Mental Health operates over 20 locations across the United States, including multiple sites in California, Illinois, Massachusetts, and Utah, with international branches in Israel and Australia. It has successfully assisted more than 30,000 individuals in reclaiming their lives through evidence-based treatments targeting anxiety, PTSD, and depression. The acquisition of Bespoke Treatment signifies not only a broader service offering but also a heightened commitment to providing individualized, compassionate care.

By fusing innovative therapies with a deep understanding of patient needs, Stella Mental Health is set to lead the way in evolving mental health care, ensuring that the most effective evidence-based treatments are readily available to those grappling with mental health challenges.

For more information, visit Stella Mental Health's official website.